Lucid Genomics Announces Compatibility Partnership with Oxford Nanopore Technologies
Lucid Genomics’ tertiary pipeline is validated for the interpretation of data generated using Oxford Nanopore sequencing.
BERLIN, Germany, May 19th, 2026 — Lucid Genomics GmbH, a bioinformatics company purpose-built for long-read sequencing, today announced a compatibility partnership with Oxford Nanopore Technologies plc. Under the partnership, Lucid Genomics’ tertiary analysis pipeline is validated for use with long and ultra-long readsdata generated on Oxford Nanopore sequencing platform.
Lucid’s tertiary engine processes basecalled, aligned, and variant-called nanopore sequencing data through annotation, variant classification, phenotype-driven case ranking, integrated handling of structural variants and methylation - all tuned for long Oxford Nanopore reads.
“This partnership highlights the importance of a strong, interoperable ecosystem to support Oxford Nanopore sequencing” said Dr. Thomas Bray, VP Corporate Business Development at Oxford Nanopore Technologies. “ Solutions such as Lucid’s pipeline help laboratories extract value from complex genomic data and integrate these workflows into existing research environments.”
A tertiary pipeline built for Nanopore data
Oxford Nanopore sequencing enables the analysis of native DNA and RNA in real time, supporting long and ultra-long reads (up to 4 Mb) and direct detection of base modifications such as 5mC and 6mA from the signal. Lucid’s tertiary pipeline carries this information end-to-end: structural variants resolved by long reads are annotated against curated disease, gene, and population datasets; methylation calls are integrated alongside sequence variants in case review; and ultra-long-range context is preserved through to the final report rather than collapsed to short-read equivalents.
What this means for Oxford Nanopore Users
For laboratories running the Oxford Nanopore sequencing platform, the partnership offers a validated route into tertiary interpretation. Customers can deploy Lucid’s cloud-native pipeline with confidence it has been tested against Oxford Nanopore data, reducing integration risk across applications spanning rare disease, hereditary cancer, and pharmacogenomics.
About Lucid Genomics
Lucid Genomics is a cloud-native secondary and tertiary analysis platform built from the ground up for long-read sequencing. Lucid Genomics develops dedicated products for rare disease diagnostics, hereditary cancer, and pharmacogenomics. As Nanopore sequencing scales, the real opportunity lies in uncovering what was previously invisible: structural variants, methylation patterns, repeat expansions, and non-coding genome regions. Lucid is a pioneer in long-read interpretation, combining proprietary prioritisation algorithms with cutting-edge visualisations purpose-built for long-read data. Together with native variant calling, advanced phasing, and annotation, this delivers a validated path from sequencer to actionable insights. As a trusted Oxford Nanopore and PacBio Compatibility partner, Lucid helps clinical labs, researchers, and pharma innovators realise the full promise of long-read genomics.
Media Contact
Lucid Genomics Communications